Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $1,670 million, representing a 6% reported growth and a 5.3% core growth compared to Q2 2024 [6][26] - Operating margin was 25.1%, and EPS was $1.31, growing 7% year over year [6][32] - The company experienced its fourth consecutive quarter of accelerating growth [7] Business Line Data and Key Metrics Changes - The Agilent CrossLab Group reported revenue of $713 million, growing 9% [27] - Life Sciences and Diagnostics Market Group revenue was $654 million, growing 3% [28] - Applied Markets Group revenue was flat at $300 million on a core growth basis [28] Market Data and Key Metrics Changes - All regions experienced growth: Americas grew low single digits, EMEA grew mid single digits, and China led with 10% growth [9][11] - India delivered high teens growth, and the company opened its first solution center in India [11] - PFAS testing grew more than 70% year over year globally, with Europe and China more than doubling their business [13][14] Company Strategy and Development Direction - The company is executing its three-year Ignite transformation strategy, which has resulted in early wins and tariff mitigation [8][20] - Agilent is focused on innovation and has launched several new products, including the Seahorse XF Flex analyzer and the InfinityLab Pro IQ series [22][23] - The company is committed to maintaining a strong balance sheet and exploring external growth opportunities [41] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about long-term growth prospects, maintaining a core growth rate of 2.5% to 3.5% for the year [25][36] - The company is proactively managing tariff exposure and expects to fully mitigate costs by fiscal 2026 [24][37] - Despite exceeding expectations in Q2, management emphasizes the importance of a disciplined outlook due to ongoing macroeconomic uncertainties [26] Other Important Information - The company has a robust pipeline of opportunities aligned with its strategy and is focused on augmenting internal innovation with external growth [41] - Agilent's digital orders grew by 12% year over year to $295 million [16] Q&A Session Summary Question: Can you provide insights on order trends during the quarter? - Orders grew low single digits in Q2, with stable business across regions and no significant pull forward from pharma tariffs [47][48] Question: What are the expectations for the NASD and BioVectra businesses? - The CDMO business is seeing high single-digit growth, with confidence in double-digit growth for the second half of the year [50][53] Question: What was the impact of tariffs on consumables? - The $15 million of consumables pulled forward was due to customer anticipation of tariffs, with no overall revenue impact for Q2 [60][61] Question: How is the Infinity Tree replacement cycle performing? - The Infinity Tree ramp is strong, with positive customer feedback and increasing adoption rates [88][89] Question: What is the outlook for pricing in light of tariffs? - The company has achieved significant pricing contributions and expects to maintain pricing strategies to mitigate tariff impacts [83][85]

FINANCIAL RESULTS OVERVIEW Q2 FY2025 May 28, 2025 Thank You for Your Attention Safe Harbor (1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX. (2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website. 03 This presentation contains forward- looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operat ...

Financial Performance - Agilent reported revenue of $1.67 billion for Q2 FY 2025, representing a growth of 6.0% reported and 5.3% core compared to Q2 FY 2024[3]. - GAAP net income for Q2 FY 2025 was $215 million, or $0.75 per share, down 29% from $308 million, or $1.05 per share in Q2 FY 2024[4]. - Non-GAAP net income for Q2 FY 2025 was $373 million, or $1.31 per share, up 7% from $356 million, or $1.22 per share in the same quarter last year[4]. - The full-year revenue outlook for FY 2025 is projected to be between $6.73 billion and $6.81 billion, indicating a growth of 3.4% to 4.6% reported[4]. - Q3 FY 2025 revenue outlook is expected to be in the range of $1.645 billion to $1.675 billion, representing an increase of 4.2% to 6.1% reported[4]. - Net income for the six months ended April 30, 2025, was $533 million, a decrease of 18.8% compared to $656 million for the same period in 2024[21]. - Non-GAAP net income for the six months ended April 30, 2025, was $750 million, representing an increase of 1.9% from $736 million in 2024[22]. Segment Performance - The Life Sciences and Diagnostics Markets Group reported Q2 revenue of $654 million, an increase of 8% reported and 3% core year-over-year[6]. - The Agilent CrossLab Group reported Q2 revenue of $713 million, an increase of 7% reported and 9% core year-over-year[6]. - The Applied Markets Group reported Q2 revenue of $301 million, a decrease of 1% reported and flat core year-over-year[7]. - Revenue for the Life Sciences and Diagnostics Markets Segment increased by 8% year-over-year, reaching $654 million in Q2 2025 compared to $604 million in Q2 2024[40]. - Revenue for the Agilent CrossLab Segment grew by 7% year-over-year, totaling $713 million in Q2 2025, up from $664 million in Q2 2024[40]. - The Applied Markets Segment reported a slight decline in revenue of 1%, with $301 million in Q2 2025 compared to $305 million in Q2 2024[40]. Cash Flow and Expenditures - Cash flows from operating activities for the six months ended April 30, 2025, were $652 million, down from $818 million in the same period of 2024[21]. - The company incurred $211 million in capital expenditures for property, plant, and equipment during the six months ended April 30, 2025, compared to $193 million in 2024[21]. - The net cash used in financing activities was $296 million for the six months ended April 30, 2025, a decrease from $531 million in 2024[21]. - The company reported a net cash increase of $157 million for the six months ended April 30, 2025, compared to an increase of $81 million in the same period of 2024[21]. Operational Insights - The gross margin for the Life Sciences and Diagnostics Markets Segment was 52.8% in Q2 2025, down from 55.1% in Q2 2024[35]. - Agilent's Ignite Transformation is driving financial success and operational excellence, becoming the core enterprise delivery engine[5]. Earnings Per Share - Non-GAAP EPS for Q3 FY 2025 is expected to be in the range of $1.35 to $1.37 per share[4].

Core Viewpoint - Agilent Technologies is expected to report quarterly earnings of $1.27 per share, a 4.1% increase year-over-year, with revenues projected at $1.63 billion, reflecting a 3.3% increase compared to the same period last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.1% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Estimates by End Markets - Revenue by End Markets- Diagnostics and Clinical is estimated at $247.93 million, a year-over-year increase of 3.7% [5]. - Revenue by End Markets- Chemical and Advanced Materials is projected to reach $370.20 million, reflecting a 2.3% increase from the previous year [5]. - Revenue by End Markets- Food is expected to be $146.05 million, indicating a 5.1% year-over-year change [5]. - Revenue by End Markets- Academia and Government is forecasted at $145.13 million, suggesting a 4.4% increase year-over-year [6]. - Net Revenue- Life Sciences and Applied Markets Group is anticipated to be $628.72 million, showing a significant decline of 16.6% year-over-year [6]. - Net Revenue- Agilent Crosslab Group is projected at $697.53 million, indicating a substantial increase of 73.5% year-over-year [6]. - Revenue by End Markets- Pharmaceutical is expected to reach $572.63 million, reflecting a 5.7% increase from the prior year [7]. - Revenue by End Markets- Environmental and Forensics is estimated at $159.54 million, indicating a 5% increase year-over-year [7]. Stock Performance - Over the past month, Agilent shares have returned 3.7%, compared to a 13.4% increase in the Zacks S&P 500 composite [7]. - Agilent currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7].

Core Insights - The article discusses the regular publication of summaries regarding new preferred stock and baby bond offerings observed by the company, indicating a focus on investment opportunities in these financial instruments [1]. Group 1 - The company typically publishes a monthly article summarizing new preferred stock and baby bond offerings [1]. - The content caters to a range of investors, from those preferring high-rated securities to those open to lower-rated options [1].

Core Viewpoint - Smackover Lithium, a joint venture between Standard Lithium and Equinor, has received unanimous approval from the Arkansas Oil and Gas Commission for its Reynolds brine production unit, marking a significant milestone for the South West Arkansas Project [1][2]. Company Overview - Standard Lithium is focused on sustainable lithium development, with a portfolio of high-grade lithium-brine properties in the U.S., particularly in Arkansas and Texas [3]. - The company aims to achieve commercial-scale lithium production through a Direct Lithium Extraction process [3]. - Standard Lithium trades on the TSX Venture Exchange and NYSE American under the symbol "SLI" [4]. Project Details - The Reynolds unit spans 20,854 acres and is expected to produce 22,500 tonnes per year of battery-quality lithium carbonate, with full commercial production anticipated by 2028 [3]. - The approval of the brine unit is a crucial step towards a final investment decision for the South West Arkansas Project and is necessary for establishing a royalty rate [2]. Partnership Insights - Equinor, an international energy company, collaborates with Standard Lithium to advance Direct Lithium Extraction projects, contributing to a low-carbon future [5]. - Equinor's portfolio includes oil, gas, renewables, and low-carbon solutions, with a goal of becoming a net-zero energy company by 2050 [5].

LEWISVILLE, Ark., April 21, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is proud to announce that its South West Arkansas ("SWA") Project has been selected as one of the first critical mineral production projects to be advanced under Executive Order 14241, Immediate Measures to Increase American Mineral Production, issued on March 20, 2025, by President Trump. This prestigious designat ...

Core Insights - Smackover Lithium, a joint venture between Standard Lithium and Equinor, has achieved a significant technical milestone in the South West Arkansas project, confirming the engineering design for commercialization [1][3] - The DLE field-pilot plant has successfully surpassed key performance criteria, recovering over 99% of lithium from brine, which is significantly higher than the design target of 95% [4] Project Development - The DLE field-pilot plant operated for three months, processing over 2,385 barrels (100,170 gallons) of brine from the IPC-1 well, completing over 497 DLE cycles [4] - The project has processed a total of 28,367,185 gallons of brine and completed 11,206 cycles of DLE at the Demonstration Plant since 2020 [4] Product Qualification - Large volumes of concentrated and purified DLE product have been sent to third-party vendors for conversion into battery-quality lithium carbonate, which will be used in the qualification process with potential off-take partners [1][4] - Approximately 970 gallons (3,672 liters) of a 6% lithium chloride solution has been produced, with expectations of generating around 27 kg of battery-quality lithium carbonate by May 2025 [4] Technology and Operations - The DLE technology utilized in the field-pilot plant is based on KTS Li-ProTM Lithium Selective Sorption technology, which has been instrumental in optimizing the extraction process [4] - Standard Lithium has been operating a large-scale Demonstration Plant in Arkansas for five years, processing over 28 million gallons of Smackover brine, which has been crucial for developing and streamlining the extraction flowsheet [3]

Core Insights - Standard Lithium Ltd. is a leading near-commercial lithium developer focused on sustainable lithium production [2] - The company will participate in the 37th Annual Roth Conference from March 16 to 18, 2025, in Dana Point, California [1] Company Overview - Standard Lithium is dedicated to the sustainable development of high-grade lithium-brine properties in the United States [2] - The company prioritizes projects with high-quality resources, robust infrastructure, skilled labor, and streamlined permitting [2] - Its flagship projects are located in the Smackover Formation in Arkansas and Texas, with a focus on commercial-scale lithium production using Direct Lithium Extraction (DLE) [2] - Standard Lithium is advancing the South West Arkansas project in partnership with Equinor and the Phase 1A project with LANXESS Corporation [2] - The company also holds interests in mineral leases in the Mojave Desert, California [2] Event Participation - Senior leadership, including the CFO and Director of Finance, will host one-on-one meetings during the Roth Conference [1] - Interested investors can contact Standard Lithium's Investor Relations for more information [1]

Financial Performance - Net revenue for the three months ended January 31, 2025, was $1,681 million, representing a 1% increase compared to the same period last year[131]. - Net income for the three months ended January 31, 2025, was $318 million, down from $348 million in the same period last year[133]. - Cash provided by operations was $431 million for the three months ended January 31, 2025, compared to $485 million in the same period last year[133]. - Total net revenue for the three months ended January 31, 2025, was $1,681 million, representing a 1% increase compared to $1,658 million in the same period last year[150]. - Income from operations for the three months ended January 31, 2025, decreased by $8 million or 2% to $376 million, despite a revenue increase of $23 million[158]. - Income from operations for the three months ended January 31, 2025, increased by $3 million or 3% on a corresponding revenue increase of $27 million[177]. Revenue Segmentation - Revenue from the Life Sciences and Diagnostics Markets segment increased by 4% year-over-year, while the Applied Markets segment saw a decrease of 4%[131]. - Revenue in the Life Sciences and Diagnostics Markets segment increased by 4% to $647 million, while the Agilent CrossLab segment saw a 1% increase to $696 million; however, the Applied Markets segment experienced a 4% decline to $338 million[150][151][152]. - Revenue in the Americas increased by 10%, while Europe saw a 3% increase; however, revenue in Asia Pacific decreased by 5%[169]. - Services and other revenue increased by 7% year-over-year, driven by strong growth in contract repair and preventative maintenance services[149]. Cost and Expenses - The total gross margin for the three months ended January 31, 2025, decreased by 1 percentage point to 53.5% compared to 54.8% in the same period last year[153][154]. - Research and development expenses decreased by 12% to $113 million, while selling, general and administrative expenses increased by 3% to $410 million[153][155][156]. - Research and development expenses decreased by 7% to $26 million for the three months ended January 31, 2025, primarily due to lower salary expenses[185]. - Selling, general and administrative expenses increased by 3% to $143 million for the three months ended January 31, 2025, due to higher corporate infrastructure expenses[186]. - Operating margin for the three months ended January 31, 2025, decreased to 31.8%, down 1 percentage point from 32.4% in the same period last year[184]. Shareholder Returns - The company paid cash dividends of $0.248 per common share, totaling $71 million, during the three months ended January 31, 2025[134]. - The 2023 share repurchase program authorized the purchase of up to $2.0 billion of common stock, with $90 million spent to repurchase 649,857 shares in the three months ended January 31, 2025[136]. - The company repurchased and retired 649,857 shares for $90 million under the 2023 repurchase program during the three months ended January 31, 2025, with remaining authorization to repurchase approximately $284 million[206]. - Cash dividends paid during the three months ended January 31, 2025, were $0.248 per common share, totaling approximately $71 million, compared to $0.236 per share or $69 million in the same period of 2024[208]. Cash Flow and Investments - Net cash provided by operating activities was $431 million for the three months ended January 31, 2025, compared to $485 million for the same period in 2024[200]. - Net cash used in investing activities was $94 million for the three months ended January 31, 2025, compared to $95 million in the same period of 2024[203]. - Investments in property, plant and equipment were $97 million for the three months ended January 31, 2025, compared to $90 million in the same period of 2024, with total capital expenditures expected to be approximately $450 million for the current year[204]. - Net cash used in financing activities for the three months ended January 31, 2025, was $180 million, a decrease from $240 million in the same period of 2024[205]. Market Outlook and Strategy - The company anticipates a steady recovery in customer capital budgets and remains optimistic about the long-term health of key end markets[137]. - The company remains optimistic about long-term growth opportunities, particularly in the life sciences and diagnostics markets, and plans to continue investing in research and development[171]. - Restructuring plans are expected to result in approximately $100 million in annual cost savings across all business segments[141]. - The organizational structure was changed in November 2024 to support a market-focused strategy, resulting in a new segmentation of business units[165]. Foreign Currency Impact - Foreign currency movements negatively impacted revenue growth by 2 percentage points for the three months ended January 31, 2025[146]. - Approximately 47% of revenue was generated in U.S. dollars during the three months ended January 31, 2025, with an unfavorable impact on revenue growth of 2 percentage points due to foreign currency exchange rate changes[220]. - Agilent CrossLab segment revenue increased by 1% year-over-year, with a 2 percentage point unfavorable impact from foreign currency movements[179]. Other Financial Information - Other income for the three months ended January 31, 2025, was $4 million, which included a net gain of $1 million on equity securities[160]. - The effective tax rate for the three months ended January 31, 2025, was 13.4%, with an income tax expense of $49 million, compared to 13.6% and $55 million in the same period last year[162]. - As of January 31, 2025, the company had no borrowings outstanding under its $1.5 billion unsecured credit facility and $750 million incremental revolving credit facility[210]. - Under the U.S. commercial paper program, the company borrowed $301 million and repaid $331 million during the three months ended January 31, 2025, with $10 million outstanding as of January 31, 2025[213]. - The company had commitments for indirect material and services increased by $12 million to $148 million, while commitments to contract manufacturers and suppliers decreased by $38 million to $603 million[217]. - There were no changes in internal control over financial reporting during the quarter ended January 31, 2025, that materially affected the company's internal control[226].